Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpha 1-blocker (bunazosin). 1992

M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
Department of Medicine, National Cardiovascular Center, Osaka, Japan.

To investigate insulin insensitivity and its reversibility, we performed an insulin sensitivity test using the steady state plasma glucose (SSPG) method in 10 lean hypertensive subjects with normal glucose tolerance before and after treatment with alpha 1-blocker bunazosin, and 14 age body mass index-adjusted healthy control subjects. Steady state plasma glucose was significantly higher in the hypertensive subjects compared with the control group (182 +/- 10 mg/dL v 104 +/- 7, P < .01, mean +/- standard error of the mean (SEM). Steady state plasma glucose significantly decreased to 136 +/- 12 mg/dL (P < .01) after the treatment with alpha 1-blocker bunazosin, with a decrease of blood pressure. Hypertensive subjects had shown an increased area under the curve of glucose and insulin during the oral glucose tolerance test compared with normal controls. The glucose area decreased significantly, but the insulin area did not change after the treatment. There was no difference in plasma epinephrine, norepinephrine, and fractional excretion of Na between normal and hypertensive subjects both before and after treatment with bunazosin at basal and during insulin sensitivity tests (2 h). Serum total cholesterol level decreased and HDL cholesterol increased significantly after treatment with bunazosin. A significant correlation was observed between SSPG and blood pressure, but not between insulin level and blood pressure. The results indicate that insulin sensitivity is better related than hyperinsulinemia to hypertension and that this insensitivity is partially reversible by alpha 1-blocker, bunazosin.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic

Related Publications

M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
May 1990, Journal of cardiovascular pharmacology,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
January 1989, European journal of clinical pharmacology,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
December 1996, Journal of hypertension,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
May 1998, Fortschritte der Medizin,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
May 1989, European journal of pharmacology,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
August 1991, Nippon Ganka Gakkai zasshi,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
September 1995, General pharmacology,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
September 1987, Hinyokika kiyo. Acta urologica Japonica,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
December 1987, Journal of hypertension,
M Suzuki, and J Hirose, and Y Asakura, and A Sato, and A Kageyama, and Y Harano, and T Omae
September 2006, Metabolism: clinical and experimental,
Copied contents to your clipboard!